TY - JOUR
T1 - Synergistic effects of nanomedicine targeting TNFR2 and DNA demethylation inhibitor— An opportunity for cancer treatment
AU - Al-Hatamleh, Mohammad A.I.
AU - Engku Nur Syafirah, E. A.R.
AU - Boer, Jennifer C.
AU - Ferji, Khalid
AU - Six, Jean Luc
AU - Chen, Xin
AU - Elkord, Eyad
AU - Plebanski, Magdalena
AU - Mohamud, Rohimah
N1 - Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/1
Y1 - 2020/1
N2 - Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer progression, metastasis and immune evasion. Although nanomedicine has been extensively studied as a carrier of cancer immunotherapeutic agents, no study to date has investigated TNFR2-targeting nanomedicine in cancer treatment. From an epigenetic perspective, previous studies indicate that DNA demethylation might be responsible for high expressions of TNFR2 in cancer models. This perspective review discusses a novel therapeutic strategy based on nanomedicine that has the capacity to target TNFR2 along with inhibition of DNA demethylation. This approach may maximize the anti-cancer potential of nanomedicine-based immunotherapy and, consequently, markedly improve the outcomes of the management of patients with malignancy.
AB - Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer progression, metastasis and immune evasion. Although nanomedicine has been extensively studied as a carrier of cancer immunotherapeutic agents, no study to date has investigated TNFR2-targeting nanomedicine in cancer treatment. From an epigenetic perspective, previous studies indicate that DNA demethylation might be responsible for high expressions of TNFR2 in cancer models. This perspective review discusses a novel therapeutic strategy based on nanomedicine that has the capacity to target TNFR2 along with inhibition of DNA demethylation. This approach may maximize the anti-cancer potential of nanomedicine-based immunotherapy and, consequently, markedly improve the outcomes of the management of patients with malignancy.
KW - Immunosuppressive
KW - Immunotherapy
KW - Nanoparticles
KW - Regulatory T cells
KW - TNF
UR - http://www.scopus.com/inward/record.url?scp=85128560898&partnerID=8YFLogxK
U2 - 10.3390/cells9010033
DO - 10.3390/cells9010033
M3 - Article
C2 - 31877663
AN - SCOPUS:85128560898
SN - 2073-4409
VL - 9
JO - Cells
JF - Cells
IS - 1
M1 - 33
ER -
